PARIS, France – September 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing ...
Interactions with self-peptide–MHC complexes on thymic epithelial cells are crucial for thymocyte survival (positive selection) and CD4 versus CD8 lineage commitment, but can also result in apoptotic ...
The issuer is solely responsible for the content of this announcement. Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...
Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback